ARCHIVES

Industry Groups Lobby for Lower Standards for FDA Approval

This article is from The Cancer Letter archive.

Vol. 37 No. 43 | November 18, 2011

Download PDF Visit The Full Archive

Related Articles

NCI Places Hold On Genentech Drug Trials, Citing Disagreement Over Intellectual Property Provisions.

March 12, 2010

NCI, Groups Disagree Over Recovery Of Funds In Cases of Scientific Fraud

October 7, 1994

Five Contracts Funded Under Unconventional Innovations Program

October 22, 1999

ACCC Statement, ASCO Comments On Health Reform

March 26, 1993

Eight Practicing Physicians On Board are Enough, Need Some Scientists Now, DeVita Says

December 9, 1983

ODAC Advice Poses Challenge to FDA: Would Iressa Approval Erode Standards?

November 8, 2002